Annovis Bio posts Q3 2025 results update

Annovis Bio, Inc. filed a current report stating that it has released its latest earnings information.

(Moderate)

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

8-K

Rhea-AI Filing Summary

Annovis Bio, Inc. filed a current report stating that it has released its latest earnings information. On November 12, 2025, the company issued a press release reporting financial results for the quarter and nine months ended September 30, 2025. The press release, which contains the detailed figures and discussion of the results, is attached to the report as Exhibit 99 and incorporated by reference.

8-K Event Classification

2 items: 2.02, 9.01

2 items

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Annovis Bio (ANVS) disclose in this 8-K filing?

Annovis Bio reported that it issued a press release on November 12, 2025, providing earnings results for the quarter and nine months ended September 30, 2025, attached as Exhibit 99.

Which period do the latest Annovis Bio (ANVS) earnings cover?

The earnings discussed relate to the quarter and nine months ended September 30, 2025.

Where can investors find the detailed Q3 2025 financial results for Annovis Bio (ANVS)?

Detailed financial results are contained in the press release furnished as Exhibit 99 to the report.

Does this Annovis Bio (ANVS) filing include full financial statements?

The report itself points to a separate press release, furnished as Exhibit 99, which contains the earnings information for the specified periods.

What exhibits are attached to the Annovis Bio (ANVS) earnings 8-K?

The report includes Exhibit 99, the earnings press release dated November 12, 2025, and Exhibit 104, the cover page interactive data file embedded within the Inline XBRL document.

Who signed the Annovis Bio (ANVS) earnings 8-K report?

The report was signed on behalf of Annovis Bio, Inc. by Maria Maccecchini, President and Chief Executive Officer.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 11/12/2025 - 05:49 PM EST

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of report (Date of earliest event reported): November 12, 2025

ANNOVIS BIO, INC.

(Exact Name of Registrant as Specified in Charter)



Delaware	001-39202	26-2540421
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(I.R.S. Employer Identification No.)

101 Lindenwood Drive, Suite 225

Malvern, PA 19355

(Address of Principal Executive Offices, and Zip Code)

(484) 875-3192

Registrant’s Telephone Number, Including Area Code

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Securities registered pursuant to Section 12(b) of the Act:


Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, par value $0.0001 per share	ANVS	New York Stock Exchange

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communication pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communication pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒

Item 2.02

Results of Operations and Financial Condition.

On November 12, 2025, Annovis Bio, Inc. (the “Registrant”) issued a press release reporting earnings for the quarter and nine months ended September 30, 2025. A copy of the press release is furnished as Exhibit 99 hereto and incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.


Exhibit No.		Description
99		Press Release dated November 12, 2025
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


	ANNOVIS BIO, INC.

Date: November 12, 2025	By:	/s/ Maria Maccecchini
		Name: Maria Maccecchini
		Title: President and Chief Executive Officer

Source: View Original Filing on SEC EDGAR